136 related articles for article (PubMed ID: 36388049)
1. A case report of pulmonary combined small cell carcinoma with enteric adenocarcinoma.
Wang S; Tan Y; Li L; Zhang Y; Liu C; Du P; Meng F; Li B
Transl Cancer Res; 2022 Oct; 11(10):3890-3894. PubMed ID: 36388049
[TBL] [Abstract][Full Text] [Related]
2. Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib.
Alkassis S; Alshare B; Ahmed S
Cureus; 2021 Jan; 13(1):e12451. PubMed ID: 33552769
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.
Shi X; Duan H; Liu X; Zhou L; Liang Z
Oncotarget; 2016 Jun; 7(23):34240-9. PubMed ID: 27145273
[TBL] [Abstract][Full Text] [Related]
5. A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review.
Xu X; Chen D; Wu X; Wang Q
Front Oncol; 2022; 12():988625. PubMed ID: 36212391
[TBL] [Abstract][Full Text] [Related]
6. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
7. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.
Li L
Heliyon; 2022 Sep; 8(9):e10407. PubMed ID: 36119883
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
[TBL] [Abstract][Full Text] [Related]
10. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
11. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
[TBL] [Abstract][Full Text] [Related]
12. Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report.
Yin Y; Qin J
Ann Palliat Med; 2021 Jun; 10(6):6990-6996. PubMed ID: 33183014
[TBL] [Abstract][Full Text] [Related]
13. Long-term complete response to gefitinib after treatment termination in a patient with recurrent post-operative
Watanabe K; Haratake N; Takenaka T; Nagano T; Oku Y; Kosai K; Ono Y; Kohno M; Oda Y
Transl Cancer Res; 2021 Nov; 10(11):5010-5013. PubMed ID: 35116352
[TBL] [Abstract][Full Text] [Related]
14. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma.
Shen C; Che G
Front Surg; 2022; 9():830849. PubMed ID: 35187062
[TBL] [Abstract][Full Text] [Related]
17. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
18. Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation.
Takagi Y; Nakahara Y; Hosomi Y; Hishima T
BMC Cancer; 2013 Nov; 13():529. PubMed ID: 24195468
[TBL] [Abstract][Full Text] [Related]
19. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
Silva NN; Eng C
J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]